drug discovery
-
MedCity Influencers, BioPharma
Machine learning: An essential tool in the shift to risk-based quality management
Risk-based quality management is a data monitoring approach that accelerates the drug development pathway without compromising on safety – and one that is enhanced by the use of technologies such as artificial intelligence.
-
Artificial Intelligence, BioPharma
GSK Digital & Tech Executive Takes Drug-Hunting Inspiration from Outer Space
GSK is making greater use of artificial intelligence and computational techniques as part of its drug discovery efforts. Speaking during the HLTH conference in Las Vegas, executive Mike Montello likened his company’s techniques to the efforts to study and analyze images from outer space.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
With Secreted Proteins Map, Juvena Finds Path to $41M for New Regenerative Meds
Juvena Therapeutics is developing secreted protein drugs built on new knowledge gleaned from proprietary technology that maps these proteins and the tissues in the body where they offer a regenerative effect. The startup’s lead program is in development for the muscle disorder myotonic dystrophy type 1.
-
Financing roundup: Neumora refuels, Ascidian ascends, Mablink’s moves & more
Odyssey Therapeutics raised $168 million in Series B financing, the largest round of funding for a biotech startup this week. Companies developing new technologies in genetic diseases, cancer, and drug research are represented also represented in this week’s recap of life science financings.
-
Artificial Intelligence, BioPharma
Stanford spinout 3T Bio snags $40M for immunotherapies targeted to solid tumors
Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.
-
BMS protein degradation drug research turns to a startup to find molecular glues
Bristol Myers Squibb’s drug R&D includes targeted protein degradation, an approach that can require proteins that don’t normally interact to find a way to stick together. BMS is turning to startup A-Alpha Bio to discover “molecular glues” that can accomplish the task.
-
Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs
Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for new neurological disorder drugs. While Cerevance’s lead program is a Parkinson’s disease drug, Merck is wants to see if the startup’s technology can help it discover and develop new Alzheimer’s disease drugs.
-
Devices & Diagnostics, Artificial Intelligence, BioPharma
Getting big pharma to embrace digital, and more from INVEST PharmaTech
Decentralized clinical trials, drug discovery technologies, and partnering strategies between big pharma and startups were among the topics covered during INVEST PharmaTech, a virtual event hosted this week by MedCity News.
-
Artificial Intelligence, BioPharma
Big tech firm Cadence expands to drug simulation software through $500M deal
Use of computational software in drug research is growing, and some big tech companies are angling for a piece of this market. Cadence Design Systems is entering the life sciences sector through the $500 million acquisition of OpenEye Scientific, a company that provides computational drug design software to the pharmaceutical industry.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Harvard spinout lands $40M to bring in vivo drug discovery to cancer
Technological advances are moving drug discovery work to computers, but experimental medicines still must be tested in animals. Startup Manifold Bio is developing technology that enables the testing of hundreds of molecules in a single mouse, bringing drug hunters valuable in vivo data much earlier in the drug discovery process.
-
New Flagship Pioneering startup expands the protein universe to fuel drug discovery
ProFound Therapeutics emerged from stealth with technology that it claims has discovered tens of thousands of previously undiscovered proteins—many of them promising new drug targets. The Flagship Pioneering-founded startup is backed by $75 million to support its drug R&D along with plans to partner with large pharmaceutical companies.
-
Novel drug-discovery approach lands big backers
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.
-
BMS joins Octant’s $80M financing and signs on as a drug discovery partner
Octant Bio’s synthetic biology approach to drug discovery is making progress, and the preclinical biotech has raised $80 million in Series B financing to continue the journey. The company added Bristol Myers Squibb as an investor and collaborator in the search for new immunology drugs.
-
Ligand Pharma turns to a SPAC to take antibody biz public, raise up to $266M
OmniAb, the antibody division of Ligand Pharmaceuticals, is set to go public through a SPAC merger that will infuse the business with up to $266 million. The deal comes as traditional IPOs have mostly ground to a halt due to uncertain market conditions, but Ligand is making a longer-term bet on growing demand for antibody drug discovery services.
-
Pharma, Artificial Intelligence, BioPharma
Celsius Therapeutics heats up with $83M and an IBD drug on path to the clinic
Single-cell analysis biotech Celsius Therapeutics has raised $83 million to advance its pipeline of drugs for autoimmune disorders and cancer. The startup’s lead autoimmune program, a TREM1-blocking antibody for inflammatory bowel disease, is expected to begin human testing in early 2023.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
